University of Sussex
Browse
Proposed primary endpoints for use in clinical trials.pdf (301.78 kB)

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Download (301.78 kB)
journal contribution
posted on 2023-06-09, 03:58 authored by P N A Harris, J F McNamara, D C Lye, J S Davis, L Bernard, A C Cheng, Y Doi, V G Fowler, K S Kaye, L Leibovici, M J Lipman, Martin LlewelynMartin Llewelyn, S Munoz-Price, M Paul, A Y Peleg, J Rodríguez-Baño, B A Rogers, H Seifert, V Thamlikitkul, G Thwaites, S Y C Tong, J Turnidge, R Utili, S A R Webb, D L Paterson
Objectives: To define standardised endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infection (BSI). Methods: Prospective studies, randomised trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process. Results: Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically-confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically-confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed. Conclusions: These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centered clinical outcomes.

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Clinical Microbiology and Infection

ISSN

1198-743X

Publisher

Elsevier

Issue

8

Volume

23

Page range

533-541

Department affiliated with

  • Global Health and Infection Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2016-11-09

First Open Access (FOA) Date

2017-04-26

First Compliant Deposit (FCD) Date

2017-04-26

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC